540 related articles for article (PubMed ID: 30029917)
1. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
[TBL] [Abstract][Full Text] [Related]
2. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
Giraud-Gatineau A; Coya JM; Maure A; Biton A; Thomson M; Bernard EM; Marrec J; Gutierrez MG; Larrouy-Maumus G; Brosch R; Gicquel B; Tailleux L
Elife; 2020 May; 9():. PubMed ID: 32369020
[TBL] [Abstract][Full Text] [Related]
3. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
[TBL] [Abstract][Full Text] [Related]
4. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
5. Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages.
Lee HJ; Ko HJ; Kim SH; Jung YJ
PLoS One; 2019; 14(3):e0199799. PubMed ID: 30865638
[TBL] [Abstract][Full Text] [Related]
6. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
8. MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2.
Kim JK; Lee HM; Park KS; Shin DM; Kim TS; Kim YS; Suh HW; Kim SY; Kim IS; Kim JM; Son JW; Sohn KM; Jung SS; Chung C; Han SB; Yang CS; Jo EK
Autophagy; 2017 Feb; 13(2):423-441. PubMed ID: 27764573
[TBL] [Abstract][Full Text] [Related]
9. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
10. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
11. Autophagy induction targeting mTORC1 enhances Mycobacterium tuberculosis replication in HIV co-infected human macrophages.
Andersson AM; Andersson B; Lorell C; Raffetseder J; Larsson M; Blomgran R
Sci Rep; 2016 Jun; 6():28171. PubMed ID: 27302320
[TBL] [Abstract][Full Text] [Related]
12. Bioenergetic Heterogeneity in Mycobacterium tuberculosis Residing in Different Subcellular Niches.
Akela AK; Kumar A
mBio; 2021 Jun; 12(3):e0108821. PubMed ID: 34060333
[TBL] [Abstract][Full Text] [Related]
13. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action.
Kim JJ; Lee HM; Shin DM; Kim W; Yuk JM; Jin HS; Lee SH; Cha GH; Kim JM; Lee ZW; Shin SJ; Yoo H; Park YK; Park JB; Chung J; Yoshimori T; Jo EK
Cell Host Microbe; 2012 May; 11(5):457-68. PubMed ID: 22607799
[TBL] [Abstract][Full Text] [Related]
14. Ambroxol Induces Autophagy and Potentiates Rifampin Antimycobacterial Activity.
Choi SW; Gu Y; Peters RS; Salgame P; Ellner JJ; Timmins GS; Deretic V
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012752
[TBL] [Abstract][Full Text] [Related]
15. Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of
Pahari S; Negi S; Aqdas M; Arnett E; Schlesinger LS; Agrewala JN
Autophagy; 2020 Jun; 16(6):1021-1043. PubMed ID: 31462144
[TBL] [Abstract][Full Text] [Related]
16. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Subbian S; Tsenova L; O'Brien P; Yang G; Koo MS; Peixoto B; Fallows D; Dartois V; Muller G; Kaplan G
PLoS Pathog; 2011 Sep; 7(9):e1002262. PubMed ID: 21949656
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
Rao M; Valentini D; Zumla A; Maeurer M
Int J Infect Dis; 2018 Apr; 69():78-84. PubMed ID: 29501835
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis.
Jain N; Kalam H; Singh L; Sharma V; Kedia S; Das P; Ahuja V; Kumar D
Nat Commun; 2020 Jun; 11(1):3062. PubMed ID: 32546788
[TBL] [Abstract][Full Text] [Related]
20. Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin.
Corrêa Barros LP; Del Rio KP; Carvalho TDSC; Pinto MDCFR; de Moura KCG; Halicki PCB; Ramos DF; da Silva PEA
Tuberculosis (Edinb); 2018 Jul; 111():198-201. PubMed ID: 30029908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
